Habitrol
This article was originally published in The Tan Sheet
Executive Summary
Ciba-Geigy transfers marketing responsibility for the prescription nicotine transdermal patch from its Rx to its OTC sales force, effective Jan. 1, in anticipation of a switch to over-the-counter status. Ciba said its smoking cessation product is in clinical trials to support OTC marketing. Habitrol sales since its 1991 launch have totaled $450 mil. in the U.S., although Ciba noted that the nicotine replacement category has declined in recent years. In a similar move, Marion Merrell Dow transferred marketing responsibility for its prescription Nicorette gum to SmithKline Beecham's consumer products group last January ("The Tan Sheet" Aug. 23, 1993, p. 1). MMD markets an Rx patch as well. Also last January, McNeil Consumer acquired U.S. and Canadian marketing rights to the Nicotrol prescription patch from Warner-Lambert
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning